|
|
 Previous Article | Table of Contents
Comparison of high-dose therapy and autologous bone marrow transplantation
for T-cell and B-cell non-Hodgkin's lymphomas
JM Vose, C Peterson, PJ Bierman, DD Weisenburger, J Linder, D Harrington, WP Vaughan, A Kessinger and JO Armitage
Department of Internal Medicine, University of Nebraska Medical Center,
Omaha 68198-3330.
Advanced T-cell non-Hodgkin's lymphoma in adults has been found to have a
poor outlook with conventional chemotherapy. To see if this extends to
patients treated with high dose therapy and autologous hematopoietic stem
cell transplantation, we reviewed the results with this treatment approach
at our institution. From October, 1983, to May, 1988, 41 patients who
underwent high-dose therapy and autologous hematopoietic stem cell
transplant for recurrent non-Hodgkin's lymphoma were re- biopsied before
transplantation to determine their immunophenotype. Seventeen of these
patients were found to have a T-cell lymphoma, and 24 had a B-cell
lymphoma. All patients were included in the intermediate or high grade
non-Hodgkin's lymphoma categories, and none were histologically transformed
from a low grade lymphoma. Analysis of the response to autologous
transplantation in these two patient populations revealed a slightly better
complete response rate for patients with T-cell lymphoma (ie, 59% versus
42%, P = NS). The actuarial 2-year survival was 35% in the T-cell group
compared with 30% in the B-cell group (P = NS). The 2-year disease-free
survival was 28% for the T-cell and 17% for the B-cell patients. Our
results with autologous transplantation for salvage therapy revealed
equivalent long- term survival and disease-free survival in both relapsed
T- and B-cell non-Hodgkin's lymphoma.
Volume 76,
Issue 2,
pp. 424-431,
07/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Reimer, T. Rudiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. K. Muller-Hermelink, and M. Wilhelm
Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study
J. Clin. Oncol.,
January 1, 2009;
27(1):
106 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Smith, J. W. Sweetenham, L. Rybicki, S. Brown, R. M. Dean, M. Kalaycio, R. Sobecks, S. Andresen, E. His, B. Pohlman, et al.
Disappointing Outcomes of Peripheral T Cell Lymphoma after Autologous Stem Cell Transplantation.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
5428 - 5428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Tisdale, A. Mahadevan, and R. H. Matthews
T-Cell Lymphoma of the Rectum in a Patient with AIDS and Hepatitis C: A Case Report and Discussion
Oncologist,
April 1, 2005;
10(4):
292 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Armitage, J. M. Vose, and D. D. Weisenburger
Towards understanding the peripheral T-cell lymphomas
Ann. Onc.,
October 1, 2004;
15(10):
1447 - 1449.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rodriguez, M. Munsell, S. Yazji, F. B. Hagemeister, A. Younes, B. Andersson, S. Giralt, J. Gajewski, M. de Lima, D. Couriel, et al.
Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas
J. Clin. Oncol.,
September 1, 2001;
19(17):
3766 - 3770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Melnyk, A. Rodriguez, W.C. Pugh, and F. Cabannillas
Evaluation of the Revised European-American Lymphoma Classification Confirms the Clinical Relevance of Immunophenotype in 560 Cases of Aggressive Non-Hodgkin's Lymphoma
Blood,
June 15, 1997;
89(12):
4514 - 4520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
